MAYTANSINE

MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.

Cross Reference

Introduction

To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with MAYTANSINE?

MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with MAYTANSINE

MeSH term MeSH ID Detail
Asthenia D001247 5 associated lipids
Body Weight D001835 333 associated lipids
Brain Diseases D001927 27 associated lipids
Breast Neoplasms D001943 24 associated lipids
Bronchial Spasm D001986 18 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Hyperplasia D006965 34 associated lipids
Hypopharyngeal Neoplasms D007012 1 associated lipids
Leukemia D007938 74 associated lipids
Leukemia P388 D007941 43 associated lipids
Per page 10 20 | Total 17

PubChem Associated disorders and diseases

What pathways are associated with MAYTANSINE

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with MAYTANSINE?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with MAYTANSINE?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with MAYTANSINE?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with MAYTANSINE?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with MAYTANSINE?

Xenograft Model

Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with MAYTANSINE

Download all related citations
Per page 10 20 50 100 | Total 611
Authors Title Published Journal PubMed Link
Ponte JF et al. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates. 2016 Bioconjug. Chem. pmid:27174129
Fan Y et al. Effects of modulation of pentose-phosphate pathway on biosynthesis of ansamitocins in Actinosynnema pretiosum. 2016 J. Biotechnol. pmid:27173582
Jacot W et al. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. 2016 Breast Cancer Res. Treat. pmid:27167986
Sandra K et al. Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine. 2016 J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. pmid:27160547
Tsuda M et al. Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: An Antibody-Drug Conjugate for Breast Cancer. 2016 Cornea pmid:27149538
de Goeij BE and Lambert JM New developments for antibody-drug conjugate-based therapeutic approaches. 2016 Curr. Opin. Immunol. pmid:26963132
Maass KF et al. Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. 2016 AAPS J pmid:26912181
Vankemmelbeke M and Durrant L Third-generation antibody drug conjugates for cancer therapy--a balancing act. 2016 Ther Deliv pmid:26893243
Raja SM et al. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. 2016 Oncotarget pmid:26859680
Kantarjian HM et al. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. 2016 Clin Lymphoma Myeloma Leuk pmid:26775883